Business
Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma
ISPOR 2023 Presentation Shows 33% Lowered Costs with Gleolan Compared to Conventional White Light...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade GliomaISPOR 2023 Presentation Shows 33% Lowered Costs with Gleolan Compared to Conventional White Light SurgeryToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today presented data demonstrating a 33% cost savings with Gleolan® (aminolevulinic acid HCl) oral solution, compared to conventional white light surgery, in US patients with high-grade glioma. The data were presented at ISPOR 2023, the annual meeting of the Professional Society for Health Economics and Outcomes Research (formerly known as the International Society for Pharmacoeconomics and Outcomes Research) in Boston, Mass.\"These latest data reinforce that the efficiencies from Gleolan clearly justify the costs in all appropriate patients in whom imaging complete resection, or ICR, is a goal of surgery,\" commented study investigator Andrew E. Sloan, MD, a neurosurgeon at Piedmont Healthcare in Atlanta, Ga.Use of Gleolan has been associated with improved imaging complete resection (ICR). In the pivotal trial leading to its approval, the ICR rate for Gleolan-guided surgery was 64%, compared to 38% for conventional white light surgery.*\"Although Gleolan is additive to the cost of surgery, its use results in lower cost per ICR, and therefore is a more efficient use of resources in the surgical resection of high-grade glioma,\" said Mark Fosdal, DHSc, PA-C, Director of Scientific Communications at Medexus.The study presented at ISPOR 2023 compared the cost per ICR with Gleolan-guided surgery (in conjunction with blue light) to that of conventional white light surgery in patients with high-grade glioma. In reviewing data from facilities representing 80% of all Gleolan utilization in the United States, the investigators calculated an average adjusted total cost savings per ICR of US$38,292 for Gleolan-guided surgery when compared to conventional white light surgery.* Gleolan (aminolevulinic acid hydrochloride [ALA-HCl]) for oral solution prescribing information. US Food and Drug Administration (FDA). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208630s000lbl.pdf. Accessed May 1, 2023.About Gleolan®Gleolan is the first and only optical imaging agent approved by the US Food and Drug Administration (FD...